Zydus Cadila gets USFDA nod for anti-viral drug
New Delhi: Drug firm Zydus Cadila said the US health regulator has given its nod to market Acylovir drug for injection used as an anti-viral chiefly in the treatment of herpes and AIDS.
"Zydus Cadila has received the final approval from the USFDA to market Acylovir for injection USP in strengths of 500 mg/vial and 1000 mg/vial," the company said in a BSE filing.
Acylovir for injection USP caters to the anti-viral segment, the company said adding that it will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The company said the group has more than 120 approvals and has so far filed over 300 ANDAs (Abbreviated New Drug Application).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd